☰

Yuwei Wang, Ph.D. - Publications

Affiliations: 
2011 Pharmaceutics and Pharmaceutical Chemistry University of Utah, Salt Lake City, UT 
Area:
Pharmacy
Tree Info Similar researchers PubMed Report error

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Wang Y, Grainger DW. Lyophilized liposome-based parenteral drug development: Reviewing complex product design strategies and current regulatory environments. Advanced Drug Delivery Reviews. PMID 30898571 DOI: 10.1016/J.Addr.2019.03.003  0.44
2014 Wang Y, Liu J, Zhang J, Wang L, Chan J, Wang H, Jin Y, Yu L, Grainger DW, Ying W. A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs. International Journal of Medical Sciences. 11: 479-87. PMID 24688312 DOI: 10.7150/Ijms.8340  0.503
2014 Ying W, Liu J, Tsang KY, Wang L, Yin H, Bai H, Wang Y, Wang L, Niitsu Y. Abstract 4578: A novel polymer-anticancer drug micelle formulation showing enhanced efficacy over Abraxane Cancer Research. 74: 4578-4578. DOI: 10.1158/1538-7445.Am2014-4578  0.307
2014 Wang Y, Grainger DW. Barriers to advancing nanotechnology to better improve and translate nanomedicines Frontiers of Chemical Science and Engineering. 8: 265-275. DOI: 10.1007/S11705-014-1442-X  0.497
2013 Wang Y, Grainger DW. Developing siRNA therapies to address osteoporosis. Therapeutic Delivery. 4: 1239-46. PMID 24116909 DOI: 10.4155/Tde.13.85  0.53
2012 Wang Y, Tran KK, Shen H, Grainger DW. Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials. Biomaterials. 33: 8540-7. PMID 22951320 DOI: 10.1016/J.Biomaterials.2012.07.039  0.529
2012 Yang D, Liu X, Jiang X, Liu Y, Ying W, Wang H, Bai H, Taylor WD, Wang Y, Clamme JP, Co E, Chivukula P, Tsang KY, Jin Y, Yu L. Effect of molecular weight of PGG-paclitaxel conjugates on in vitro and in vivo efficacy. Journal of Controlled Release : Official Journal of the Controlled Release Society. 161: 124-31. PMID 22521595 DOI: 10.1016/J.Jconrel.2012.04.010  0.303
2012 Wang Y, Grainger DW. RNA therapeutics targeting osteoclast-mediated excessive bone resorption. Advanced Drug Delivery Reviews. 64: 1341-57. PMID 21945356 DOI: 10.1016/J.Addr.2011.09.002  0.529
2011 Wang Y, Panasiuk A, Grainger DW. Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures. Molecular Pharmaceutics. 8: 1016-24. PMID 21186792 DOI: 10.1021/Mp100374N  0.536
2010 Takahashi H, Wang Y, Grainger DW. Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation. Journal of Controlled Release : Official Journal of the Controlled Release Society. 147: 400-7. PMID 20727922 DOI: 10.1016/J.Jconrel.2010.08.019  0.496
2010 Wang Y, Grainger DW. siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption. Pharmaceutical Research. 27: 1273-84. PMID 20333451 DOI: 10.1007/S11095-010-0099-5  0.535
Show low-probability matches.